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Summary Introduction This phase 1 study assessed safety,
maximum tolerated dose (MTD), pharmacokinetics, cere-
brospinal fluid (CSF) distribution, and preliminary clinical
activity of the receptor tyrosine kinase inhibitor TAK-285.
Methods Patients with advanced, histologically confirmed
solid tumors and Eastern Cooperative Oncology Group per-
formance status ≤2 received daily oral TAK-285; daily dose
was escalated within defined cohorts until MTD and recom-
mended phase 2 dose (RP2D) were determined. Eleven
patients were enrolled into an RP2D cohort. Blood samples
were collected from all cohorts; CSF was collected at phar-
macokinetic steady-state from RP2D patients. Tumor
responses were assessed every 8 weeks per Response
Evaluation Criteria in Solid Tumors. Results Fifty-four pa-
tients were enrolled (median age 60; range, 35–76 years).
The most common diagnoses were cancers of the colon
(28 %), breast (17 %), and pancreas (9 %). Escalation cohorts
evaluated doses from 50 mg daily to 500 mg twice daily; the
MTD/RP2D was 400 mg twice daily. Dose-limiting toxic-
ities included diarrhea, hypokalemia, and fatigue. Drug ab-
sorption was fast (median time of maximum concentration
was 2–3 h), and mean half-life was 9 h. Steady-state average
unbound CSF concentration (geometric mean 1.54 [range,
0.51–4.27] ng/mL; n=5) at the RP2D was below the 50 %
inhibitory concentration (9.3 ng/mL) for inhibition of
tyrosine kinase activity in cells expressing recombinant
HER2. Best response was stable disease (12 weeks of
nonprogression) in 13 patients. Conclusions TAK-285 was
generally well tolerated at the RP2D. Distribution in human
CSF was confirmed, but the free concentration of the drug
was below that associated with biologically relevant target
inhibition.
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Introduction
The human epidermal growth factor receptors EGFR
(erbB1) and HER2 (erbB2) play critical roles in cell growth
and proliferation [1], and have upregulated activity in vari-
ous cancers [2]. Up to 25 % of patients with breast cancer are
HER2-positive (HER2+), and HER2+ patients have a poor
prognosis and a higher chance of relapse [3]. Therapy spe-
cifically targeting erbB kinases has become an important part
of clinical management; the standard of care for patients with
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HER2+ breast cancer includes trastuzumab, a humanized
monoclonal antibody that inhibits HER2 activity [4].
Although therapy with trastuzumab provides clinical benefit,
many patients eventually become resistant [5–8]. In addition,
more than 25 % of HER2+ patients treated with trastuzumab
will develop brain metastases [9]; in that event, monoclonal
antibodies are of limited use because they cannot readily cross
the blood–brain barrier (BBB) [10]. Lapatinib, a small-
molecule HER2 inhibitor, has demonstrated only negligible
central nervous system (CNS) penetration across either an
intact [11] or a tumor-compromised BBB [12], and has low
clinical activity in this setting [13, 14]. Many traditional
chemotherapeutic agents likewise have poor CNS distribution
[15–17]. Therefore, there is an unmet need for more effective
therapies for patients with HER2+ brain metastases.
TAK-285 is an investigational, small-molecule tyrosine
kinase inhibitor [18]. It has been shown to be both selective
and potent [19]; in vitro 50 % inhibitory concentration (IC50)
values for recombinant human EGFR and HER2 are 23 and
17 nmol/L, respectively [20]. Preclinical studies suggest that
TAK-285 inhibits the growth of malignant cell lines [21], has
antitumor activity in murine xenograft models, and inhibits
mutant EGFR kinase activity (L858R and L861Q) [22]
(Nakayama et al., unpublished data, 2012); however, TAK-
285 did not inhibit the growth of the EGFR mutant NSCLC
cell line HCC4006 (data on file). In vitro transport studies
suggest that TAK-285 is not a substrate for the BBB efflux
transporters P-glycoprotein (P-gp) or breast cancer resistance
protein (BCRP), and TAK-285 exhibits high transcellular
permeability [23] (Nakayama et al., unpublished data,
2012). In vivo preclinical CNS distribution studies have
demonstrated that in rats TAK-285 penetrates the BBB and
distributes into brain tissue and interstitial fluid [23, 24].
In a preliminary phase 1 study of TAK-285 in Japanese
patients with advanced cancers (N=26), patients in dose-
escalation cohorts received TAK-285 once weekly for
3 weeks followed by 1 week of observation; in a repeated-
administration cohort at the maximum tolerated dose (MTD;
found to be 300 mg twice daily [BID]), patients received
TAK-285 for at least 4 weeks. The treatment was generally
well tolerated, and 1 patient with parotid cancer experienced
a partial response [25]. The present phase 1 study was
undertaken to evaluate the safety (MTD, recommended
phase 2 dose [RP2D], dose-limiting toxicities [DLTs]),
antitumor activity, and pharmacokinetic properties of TAK-
285 in patients with advanced cancer refractory to standard
cancer therapy. In addition, this study evaluated CSF distri-
bution of TAK-285 at pharmacokinetic steady-state to deter-
mine whether biologically relevant concentrations are
achievable in the human CNS at tolerable doses and to assess
the utility of TAK-285 as a potential investigational agent for
treating and/or preventing brain metastases in patients with
HER2+ metastatic breast cancer.
Methods
Patients
Eligible patients were 18 years of age or older with a diag-
nosis of advanced, histologically confirmed solid tumors
refractory to other therapy. Patients were to have Eastern
Cooperative Oncology Group performance status ≤ 2, ade-
quate hematologic (absolute neutrophil count ≥ 1,500 cells/
mm3, hemoglobin ≥ 9 g/dL, platelet count ≥ 100,000/mm3),
hepatic (total bilirubin ≤1.5× upper limit of normal [ULN],
aspartate aminotransferase [AST] and alanine aminotransfer-
ase [ALT] ≤ 2.5× ULN), and renal (serum creatinine ≤ 1.5×
ULN) function. Patients enrolled in the RP2D cohort were to
have left ventricular ejection fraction ≥ 50 % and be able to
tolerate a single lumbar puncture for collection of CSF.
Major exclusion criteria included current CNS metastases
or primary CNS malignancy, significant electrocardiogram
abnormalities including QTc prolongation (> 450 ms for men
and >470 ms for women), any other cancer (other than
nonmelanoma skin cancer or cervical cancer in situ) unless
in complete remission and off all therapy for ≥ 3 years,
cardiovascular impairment, pleural or pericardial effusion,
active gastrointestinal bleeding or ulceration, systemic treat-
ment with strong or moderate cytochrome P445 (CYP)3A4
inducing/inhibiting drugs within 14 days before study en-
rollment, and life expectancy less than 12 weeks. The study
was conducted in accordance with good clinical practice and
the general principles of the Declaration of Helsinki. All
patients provided signed informed consent before initiation
of any study procedures.
Study design
This was a 3-center, multicohort, open-label, nonrandomized,
noncomparative, clinical and pharmacokinetic study of TAK-
285 in patients with advanced cancer (NCT00535522). The
primary objectives of the study were to determine the safety
(MTD, RP2D, DLTs) and pharmacokinetic profile (both plas-
ma and CSF concentrations) of the drug. A series of dose-
escalation cohorts was used to establish the MTD and RP2D
(Fig. 1). The starting dose of TAK-285 was 50 mg daily (QD);
the drug was initially administered on days 1 through 21 of a
28-day cycle (50 mg QD, 50 mg BID, and 75 mg BID co-
horts). On observation that TAK-285 was generally well tol-
erated, the dose was escalated to 500 mg, and patients in the
remaining cohorts (150 mg BID to 500 mg BID) received the
drug daily. Three to 6 patients were recruited at each dose
level; once the MTD was established, additional patients were
enrolled at that level in an RP2D expansion cohort. The
protocol specified that the RP2D expansion cohort would
further test the MTD using an initial regimen of dosing on
days 1 through 21 during cycle 1 to confirm safety and
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tolerability, then daily (without days off) during subsequent
cycles. The MTD was defined as the dose level immediately
below that in which ≥ 2 patients experienced DLTs during the
first 28 days of treatment (cycle 1); only DLTs during cycle 1
affected dose escalation decisions for subsequent cohorts. A
DLT was defined as any grade ≥ 4 hematologic toxicity, any
grade ≥ 3 nonhematologic toxicity (other than nausea,
vomiting, and diarrhea that could be controlled with standard
supportive care), grade 3 QTc prolongation (> 500 ms
assessed by a qualified reader and confirmed on a repeat
electrocardiogram), or any TAK-285–related toxicity resulting
in a treatment delay of > 21 days.
Assessments
The primary endpoints of the study were the safety and
pharmacokinetics of TAK-285. Safety of TAK-285 was
assessed by physical examination, vital signs, electrocardio-
gram changes, laboratory evaluations, and occurrence of
adverse events (AEs). Adverse events were evaluated at each
study visit and were graded using the National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 3.0. The secondary endpoint was therapeutic
efficacy of TAK-285. Disease assessments (computed
tomography, magnetic resonance imaging, x-ray and/or bone
scans) were performed at baseline, after cycle 2, and every
8 weeks thereafter according to Response Evaluation Criteria
in Solid Tumors [26]. Stable disease was defined as no tumor
growth for a minimum of 12 weeks.
Pharmacokinetic assessments and data analyses
During cycle 1, blood samples for pharmacokinetic analysis
were collected on day 1 from patients in the dose-escalation
cohorts starting before treatment, and at 0.5, 1, 2, 3, 4, 6, 8,
12, and 24 h after the morning dose. Blood sample collection
on day 21 of cycle 1 followed the same schedule, with the
additional collection of samples 48 and 72 h after dosing. On
days 8 and 15, predose (trough) blood samples were collect-
ed in the morning.
For patients in the RP2D cohort, blood samples were
collected on days 1, 8, and 15 of cycle 1 as described above.
The evening dose on day 1 was not administered in this
cohort to permit characterization of the pharmacokinetic
profile from 0 to 24 h after day 1 dosing. On day 22, (ie,
day 21 of BID administration), samples were collected as on
day 1, with additional samples collected at 48, 72, and 120 h
after dosing to characterize steady-state terminal distribution
Patients with qualifying malignancy
(N = 54)
Cohort 1:






Days 1 to 21 of a
28-day cycle (Cycle 1)
then administered
daily (Cycle 2+)
TAK-285 50 mg QD (n = 4)
Cohort 2:
TAK-285 50 mg BID (n = 7)
Cohort 3
TAK-285 75 mg BID (n = 6)
Cohort 4:
TAK-285 150 mg BID (n = 6)
Cohort 5:
TAK-285 225 mg BID (n = 4)
Cohort 6:
TAK-285 325 mg BID (n = 3)
Cohort 7:
TAK-285 400 mg BID (n = 6)
Cohort 8:
TAK-285 500 mg BID (n = 7)
RP2D Cohort:
TAK-285 400 mg BID (n = 11)
Fig. 1 Dosing chart. BID,
twice daily; QD, once daily;
RP2D, recommended phase 2
dose
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half-life (t½). On day 15 of cycle 1, CSF samples were
collected by lumbar puncture 3 to 4 h after dosing for CSF
TAK-285 concentration and protein binding measurements;
concurrent blood samples were also obtained for plasma
TAK-285 concentration and protein binding measurements.
TAK-285 concentrations in plasma and CSF were mea-
sured by high-performance liquid chromatography/tandem
mass spectrometry. Plasma and CSF protein binding were
measured using equilibrium dialysis. Pharmacokinetic pa-
rameters were calculated from concentration-time data using
standard noncompartmental methods (WinNonlin v.5.2) and
included the maximum plasma concentration (Cmax), the
time of first occurrence of Cmax (Tmax), the area under the
plasma concentration-time curve from time zero to the end of
the dosing interval (AUC0-τ), steady-state average concen-
tration over the dosing interval (Css,avg), peak-trough ratio
(PTR), accumulation ratio (Rac), and t½. In the RP2D cohort,
additional pharmacokinetic endpoints included the free frac-
tions of TAK-285 in plasma (fu,p) and CSF (fu,CSF), and the
steady-state unbound CSF/unbound plasma concentration
ratio (Cu,CSF:Cu,p). The unbound steady-state average con-
centrations of TAK-285 in CSF (Css,avg,u,CSF) were calculat-
ed using Eq. 1 from individual patient values of day 22
plasma Css,avg, total CSF (CCSF) and corresponding total
plasma (Cp) TAK-285 concentrations at the time of lumbar
puncture on day 15, and the CSF free fraction (fu,CSF).
Css;avg;u;CSF ¼ Css;avg  CCSFCp  f u;CSF ð1Þ
The above calculation assumes that distributional equilib-
rium is achieved by day 15 of BID dosing in the CSF
compartment and that the CSF-plasma concentration ratio
measured at approximately plasma Tmax on day 15 (ie, under
pharmacokinetic steady-state conditions in plasma) is repre-
sentative of the CSF-plasma concentration ratio over the
entire dosing interval.
Statistical analysis
Descriptive statistical analyses were conducted for patient
demographic and baseline characteristics; summary statistics
(mean, median, maximum, minimum, standard deviation,
and 95 % confidence interval [CI]) were used to evaluate
safety and efficacy. Plasma and CSF pharmacokinetic pa-
rameters were summarized using descriptive statistics (arith-
metic and geometric means, standard deviation, percentage
coefficient of variation [%CV], median, minimum, maxi-
mum). Dose-proportionality was assessed using power mod-
el analysis. A linear regression was performed on log-
transformed Css,avg versus log-transformed daily dose using
SigmaPlot for Windows, version 11.0, and the 95 %CI of the




Between August 2007 and June 2011, 54 patients were
enrolled and treated with at least 1 dose of TAK-285.
Patient characteristics were similar between treatment
groups (Table 1) [27]. The most common malignancies were
colon (28 %), breast (17 %), and pancreatic cancer (9 %).
Most patients had received prior chemotherapy. Five patients
(9 %) had received prior treatment with trastuzumab for
HER2+ breast cancer.
Dose escalation and safety
Dose levels were escalated in 8 cohorts as follows: 50 mg
QD (n=4), 50 mg BID (n=7), 75 mg BID (n=6), 150 mg
BID (n=6), 225 mg BID (n=4), 325 mg BID (n=3), 400 mg
BID (n=6), and 500 mg BID (n=7). Patients in the 50 mg
QD, 50 mg BID, and 75 mg BID cohorts received the study
drug on days 1 through 21 of a 28-day cycle. Patients in all
other dose-escalation cohorts received the drug daily with no
days off. Two of the 7 patients at the highest dose level
(500 mg BID) experienced DLTs that resulted in dose inter-
ruption (Table 2). Therefore, dose escalation was stopped
and 400 mg BID was established as the MTD and RP2D.
Eleven additional patients were enrolled in the 400 mg BID
RP2D expansion cohort. Three patients in the RP2D cohort
experienced DLTs during cycle 1 that led to drug interruption
or dose reduction (Table 2). Three other patients in the dose-
escalation cohorts experienced DLTs leading to drug with-
drawal, dose reduction, or dose interruption during cycle 1
(Table 2). One additional patient experienced grade 4 rhab-
domyolysis, elevated creatine kinase and AST, and grade 3
elevated ALT after cycle 1, and study drug was withdrawn.
Most patients (98 %) experienced at least 1 AE, and most
AEs were grade 1 or 2. The most common treatment-
emergent AEs were diarrhea (46 %), fatigue (44 %), and
nausea (32 %) (Table 3). Twenty-eight patients (52 %) ex-
perienced grade ≥ 3 AEs. The most common grade ≥ 3 AEs
were hypokalemia and diarrhea (Table 3). Twenty-five pa-
tients (46 %) experienced serious AEs. Serious AEs ob-
served in ≥ 2 patients were disease progression, deep vein
thrombosis, ileus, bowel obstruction, abdominal pain, back
pain, dyspnea, and hyponatremia. Nine patients experienced
AEs that led to discontinuation of the study drug: 3 patients
in the 50 mg BID cohort, 2 patients in the 150 mg BID
cohort, and 1 patient in each in the 325 mg BID, 400 mg
BID, 500 mg BID, and RP2D cohorts. Five patients died
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during the study (within 30 days of the last dose of study
drug): 4 due to disease progression and 1 due to intestinal
obstruction. None of these deaths was considered related to
study drug.
Pharmacokinetics
After oral administration, absorption of TAK-285 was fast;
peak plasma concentrations were achieved 2 to 3 h postdose.
Plasma exposures of TAK-285 increased with increasing dose
(Fig. 2a and b; Table 4). The extent of accumulation was
approximately 3-fold at the MTD of 400 mg BID (Fig. 3;
Table 4). In the 400 mg BID dosing group, after cessation of
multiple-dose administration, there was an approximately
monoexponential decline in plasma concentrations with a
mean t½ of 8.9±0.99 h (Fig. 2c). Pharmacokinetic steady-
state conditions were achieved by day 8, based on similar
trough concentrations on days 8, 15, and 21 (data not shown).
Fluctuation over the steady-state dosing interval, measured as
PTR, decreased with BID dosing compared with QD dosing
(Table 4). On day 21, the PTR was ~2.8 at the MTD of
400 mg BID (Fig. 3).
Table 1 Patient demographics
Dose-escalation cohorts RP2D expansion cohort Total
(n=43) (n=11) (N=54)
Median age, years (range) 60 (43–76) 59 (35–73) 60 (35–76)
Female, n (%) 22 (51) 7 (64) 29 (54)
White, n (%) 37 (86) 10 (91) 47 (87)
ECOG PS, n (%)
0 11 (26) 4 (36) 15 (28)
1 30 (70) 6 (55) 36 (67)
2 2 (5) 1 (9) 3 (6)
Primary tumor type, n (%)
Colon cancer 11 (26) 4 (36) 15 (28)
Breast cancer 6 (14) 3 (27) 9 (17)
Pancreatic cancer 4 (9) 1 (9) 5 (9)
Ovarian cancer 3 (7) 1 (9) 4 (7)
Rectal cancer 2 (5) 0 2 (4)
Esophageal cancer 2 (5) 0 2 (4)
Othera 14 (33) 2 (18) 16 (30)
Prior therapy, n (%)
Chemotherapy 41 (95) 10 (91) 51 (94)
Radiotherapy 21 (49) 4 (36) 25 (46)
Hormonal/immuno/biologic 22 (51) 9 (82) 31 (57)
ECOG PS Eastern Cooperative Oncology Group performance status, RP2D recommended phase 2 dose
a Other primary malignancies included melanoma, non-small cell lung cancer, gastric cancer, bladder cancer, anal cancer, head and neck cancer,
periampullary adenocarcinoma, squamous cell carcinoma, angiosarcoma, basal cell carcinoma, adenoid cystic carcinoma, urothelial carcinoma, clear
cell carcinoma, ampulla of Vater carcinoma, multiple calcified granulomas, mesothelioma, and pleural cavity cancer
Reprinted with permission from Chiorean et al. [27]
Table 2 Dose-limiting toxicities at each dose level during cycle 1
Dose Number of
patients, n/N
DLT (number of events)
50 mg BID 1/4a Grade 3 pancreatitis (1)
150 mg BID 1/6a Grade 3 chest pain (1)
Grade 3 dyspnea (1)
Grade 3 hypoxia (1)
400 mg BID 2/6b Grade 3 worsening
hyperbilirubinemia (1)
Grade 3 ALT increase (1)
500 mg BID 2/7b Grade 3 diarrhea (2)
Grade 3 nausea (1)
Grade 3 vomiting (1)
Grade 3 hypokalemia (1)
RP2D-400 mg BID 3/11c Grade 3 fatigue (2)
Grade 3 diarrhea (1)
ALT alanine aminotransferase, BID twice daily, DLT dose-limiting
toxicity, RP2D recommended phase 2 dose
a Drug withdrawn
b Treatment interrupted (n=1)
c Dose reduced (n=2), treatment interrupted (n=1)
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Steady-state exposures of TAK-285 increased in a greater
than dose-proportional manner; a 10-fold increase in dose
(from 50 mg BID to 500 mg BID) was associated with a 29-
fold increase in geometric mean steady-state AUC0-τ (Table 4).
The slope of the linear regression of log (Css,avg) versus log
(Dose) was estimated to be 1.43 (95 % CI, 1.26–1.59; Fig. 2d).
CSF distribution
To assess the distribution of TAK-285 to the CNS, CSF
samples were obtained from 7 patients in the RP2D cohort
at 3 to 4 h postdose on day 15. TAK-285 was highly protein
bound in plasma, with a mean plasma free fraction of 0.1 %
(n=7) (Table 5). The mean free fraction in CSF was 23.7 %
(n=7). Variability in plasma and CSF protein binding was
moderate (%CV, ~35 %). At the time of CSF collection, the
mean Cu,CSF:Cu,p ratio was 0.663 (%CV, 23 %; n=7) indicat-
ing that the CSF contained, on average, 66 % of systemically
available unbound TAK-285. The range of individual values
of the Cu,CSF:Cu,p ratio was approximately 2-fold, indicating
relatively low interpatient variability in CNS distribution of
TAK-285 when normalized for unbound systemic exposures.
Excellent correlation was observed between the measured
unbound CSF concentrations and concurrently measured un-
bound plasma concentrations of TAK-285 (r2=0.95; n=7;
Fig. 4a). The geometric mean Css,avg,u,CSF was 1.54 ng/mL
(%CV, 74 %; n=5); individual values of this parameter varied
from 0.51 to 4.27 ng/mL and all were below the HER2 IC50 of
9.3 ng/mL (Fig. 4b).
Efficacy
No patient experienced a complete or partial response to TAK-
285 [27]. The best response was stable disease, which was
observed in 9 of 33 patients (27 %) in the dose-escalation
cohorts and 4 of 8 patients (50 %) in the RP2D cohort. The
clinical benefit rate (proportion of patients with complete re-
sponse, partial response, or stable disease durable for >6 cycles)
was 9 % (3 patients) in the dose-escalation cohorts and 13 % (1
patient) in the RP2D cohort. Disease stabilization was reported
Table 3 Adverse events
Most common AEs, all grade Most common grade≥3 AEs (n≥2)
Treatment-emergent Drug-related
AE, n (%) Dose-escalation cohorts RP2D cohort Total Dose-escalation cohorts RP2D cohort Total Total
(n=43) (n=11) (N=54) (n=43) (n=11) (N=54) (N=54)
Diarrhea 17 (40) 8 (73) 25 (46) 2 (5) 1 (9) 3 (6) 3 (6)
Fatigue 17 (40) 7 (64) 24 (44) 0 2 (4) 2 (4) 2 (4)
Nausea 13 (30) 4 (36) 17 (31) 0 0 0 0
Anorexia 9 (21) 4 (36) 13 (24) 0 0 0 0
Elevated AST 11 (26) 2 (18) 13 (24) 0 0 0 0
Vomiting 9 (21) 3 (27) 12 (22) 0 0 0 0
Peripheral edema 6 (14) 3 (27) 9 (17) 0 0 0 0
Rash 5 (12) 4 (36) 9 (17) 0 0 0 0
Abdominal pain 6 (14) 2 (18) 8 (15) 2 (5) 0 2 (4) 0
Increased blood AP 7 (16) 0 7 (13) 0 0 0 0
Constipation 4 (9) 3 (27) 7 (13) 0 0 0 0
Increased ALT 5 (12) 1 (9) 6 (11) 0 0 0 0
Back pain 4 (9) 2 (18) 6 (11) 0 0 0 0
Dyspnea 5 (12) 1 (9) 6 (11) 2 (5) 0 2 (4) 1 (2)
Hyponatremia 4 (9) 2 (18) 6 (11) 1 (2) 1 (9) 2 (4) 0
Anemia 3 2 5 1 (2) 1 (9) 2 (4) 1 (2)
DVT 2 0 2 2 (5) 0 2 (4) 0
Elevated INR 2 0 2 2 (5) 0 2 (4) 0
Hypoxia 2 0 2 2 (5) 0 2 (4) 1 (2)
Hypokalemia 5 0 5 4 (9) 0 4 (7) 1 (2)
Ileus 2 0 2 2 (5) 0 2 (4) 0
Small bowel obstruction 1 1 2 1 (9) 1 (9) 2 (4) 0
AE adverse event, ALT alanine aminotransferase, AP alkaline phosphatase, AST aspartate aminotransferase, DVT deep vein thrombosis, INR
international normalized ratio, RP2D recommended phase 2 dose
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in patients with breast cancer (n=2; 1 patient each in the
500mgBID andRP2D cohorts), ovarian cancer (n=2; 1 patient
each in the 50 mg BID and RP2D cohorts), head and neck
cancer (n=1; 75 mg BID), non-small-cell lung cancer (n=1;
75 mg BID), skin cancer (n=1; 150 mg BID), angiosarcoma
(n=1; 150 mg BID), clear-cell carcinoma (n=1; 325 mg BID),
gastric cancer (n=1; 400 mg BID), ampulla of Vater adenocar-
cinoma (n=1; 400 mg BID), melanoma (n=1; RP2D), and
squamous cell anal carcinoma (n=1, RP2D). Both breast can-
cer patients with stable disease were HER2+; each had been
previously treated with trastuzumab and 1 had been previously
treated with lapatinib.
Discussion
TAK-285, an orally active multikinase inhibitor, was gener-
ally well tolerated at the MTD/RP2D of 400 mg BID. The
most frequent AEs encountered at that dose level were diar-
rhea, fatigue, nausea, anorexia, and rash; therefore, the safety
profile of TAK-285 was similar to that of other EGFR/HER2
inhibitors such as lapatinib [28, 29], and no unexpected AEs
emerged during the trial. Pharmacokinetic analysis indicated
that TAK-285 absorption was fast, with peak drug concen-
trations achieved 2 to 3 h postdose. Steady-state exposures
increased with increasing dose, with evidence for a moderate
degree of supra-proportionality in the dose-exposure rela-
tionship over the 50 mg BID to 500 mg BID dose range. As
the clearance mechanisms of TAK-285 in humans in vivo are
not definitively elucidated, the specific reasons for this ob-
servation are not currently known. The t½ of TAK-285 was
approximately 9 h, supporting BID dosing in this study.
Approximately 3-fold accumulation with BID dosing was
observed at the MTD of 400 mg (Fig. 2a; Table 4). Steady-
state pharmacokinetics was achieved by day 8, consistent
with the estimated t½. Pharmacokinetic variability in steady-
state systemic exposures of TAK-285 was relatively high
(%CV in AUC0-τ of 58 % at the MTD of 400 mg BID;
Table 4) despite low variability in the steady-state t½ (%CV
of 11 %). These observations suggest that the variability in
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Fig. 2 Mean plasma concentration-time profiles of TAK-285. a and
b Overlays of the mean concentration-time profiles from patients in
the dose-escalation cohorts (50 mg once daily [QD] to 500 mg twice
daily [BID]) measured on (a) day 1 and on (b) day 21. c Semilog-
arithmic plot of the concentration-time profile at steady-state to
display the terminal disposition phase following cessation of multiple
dosing. d Relationship between total daily dose of TAK-285 and the
steady-state average concentration (Css,avg). The symbols represent
individual patients; the solid line is the power model-predicted dose-
Css,avg relationship, and the dashed lines represent the 95 % confidence
interval of the model-predicted relationship
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systemic exposures of TAK-285 is likely explained by
interindividual variability in bioavailability (absorption
and/or first-pass metabolism by CYP3A4 in the intestine
and liver) rather than variability in systemic clearance. The
best response to TAK-285 in this study was stable disease in
13 patients. Among the 54 patients enrolled, 9 had breast
cancer (7 HER2+), and 2 of the HER2+ patients had stable
disease.
A major consideration that led to the present study with
TAK-285 is the high incidence of brain metastases in HER2+
breast cancer and the significant unmet need for more effec-
tive therapy for these patients. Preclinical studies suggest
that TAK-285 crosses the intact BBB in rats and is not a
substrate for the BBB efflux transporters MDR1 P-gp or
BCRP—features that may distinguish it from the
EGFR/HER2 inhibitor lapatinib, which has been evaluated
in this setting [11]. Therefore, a unique aspect of this phase 1
study was the characterization of the distribution of TAK-
285 into CSF in an expansion cohort dosed at the
MTD/RP2D to determine whether bioactive exposures of
TAK-285 are achievable in human CNS. The use of CSF
distribution as a surrogate of distribution to brain interstitial
fluid (ISF) is supported by preclinical data in rats, which
suggested quantitatively similar extents of distribution into
the CSF and ISF and the lack of meaningful CSF-ISF gradi-
ents [23]. TAK-285 displayed good CSF distribution, with
the unbound concentrations achieved in CSF averaging 66 %
of what would be theoretically achievable in the setting of
Table 4 Pharmacokinetic parameters of TAK-285 after multiple-dose administration





50 mg QD 1 4 170 (31.8) 2.00 (2.00–6.00) 1220 (47.6) NA NA
21 3 241 (50.0) 4.00 (2.00–6.00) 2280 (19.1) 13.68 (11.0) 1.52 (0.52)
50 mg BID 1 7 179 (40.6) 2.00 (1.08–4.02) 987 (27.3) NA NA
21 5 197 (43.7) 2.00 (2.00–3.00) 1240 (62.9) 5.25 (2.85) 1.41 (0.45)
75 mg BID 1 6 231 (18.8) 2.07 (1.00–6.00) 1410d (33.0) NA NA
21 6 369 (17.1) 2.00 (1.00–3.00) 2370 (11.0) 3.58 (1.53) 1.80d (0.53)
150 mg BID 1 6 368 (30.7) 2.00 (2.00–3.00) 2340 (31.1) NA NA
21 5 837 (54.1) 2.00 (1.00–4.00) 6490 (48.4) 2.35 (0.32) 3.06 (0.98)
225 mg BID 1 4 475 (59.9) 2.50 (2.00–3.08) 2610 (40.3) NA NA
21 3 1760 (11.3) 2.00 (1.08–3.00) 16200 (7.80) 1.57 (0.29) 7.06 (2.61)
325 mg BID 1 3 675 (65.4) 3.00 (1.00–4.00) 3930 (97.9) NA NA
21 3 1970 (48.4) 2.00 (2.00–2.00) 14200 (65.0) 2.81 (1.43) 3.79 (1.49)
400 mg BID 1 17 1140 (40.4) 2.00 (2.00–6.03) 7700 (43.9) NA NA
21 9 3180 (46.0) 2.00 (1.00–4.08) 23400e (58.5) 2.77e (2.02) 3.26e (1.58)
500 mg BID 1 7 1250 (53.6) 2.00 (1.00–5.98) 8360f (36.6) NA NA
21 4 4160 (35.7) 2.00 (1.00–4.00) 35800 (35.2) 1.88 (0.36) 5.07 (3.18)
AUC0-τ area under the plasma concentration-time curve from time zero to the end of the dosing interval; BID twice daily; Cmax maximum plasma
concentration; NA not applicable; PTR peak-trough ratio; QD once daily; Rac accumulation ratio; Tmax time of first occurrence of Cmax



































Fig. 3 Mean plasma concentration-time profiles on days 1 and 21 of
multiple-dose administration of TAK-285 after twice daily (BID) re-
peat-dose administration at the maximum tolerated dose (MTD) of
400 mg BID in patients with advanced nonhematologic malignancies.
The panel shows an overlay of the day 1 and day 21 steady-state mean
concentration-time profiles to display the extent of accumulation
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unrestricted distribution of unbound drug from plasma to CSF.
Excellent correlation was observed between the measured
unbound CSF concentrations and concurrently measured un-
bound plasma concentrations of TAK-285 (Fig. 4a). Between-
patient variability in unbound CSF TAK-285 concentration is
explained largely by between-patient variability in systemic
exposures of TAK-285 (Table 4) and is not reflective of
variability in CNS distributional processes. The individual
ratios of the measured CSF TAK-285 concentrations at 3 to
4 h postdose on day 15 (ie, at pharmacokinetic steady-state) to
the corresponding plasma concentrations measured at the
same time, together with individual values of TAK-285 free
fraction in CSF and plasma Css,avg were used to calculate
individual values of steady-state average unbound concentra-
tions achieved in CSF using Eq. 1. An important assumption
underlying this calculation is that the measured CSF-plasma
concentration ratio at 3 to 4 h postdose on day 15 is a
reasonable estimate of the CSF-plasma concentration ratio
over the entire steady-state dosing interval. This assumption
is supported by the high transmembrane permeability of TAK-
285, in vitro data that it is not a substrate for BBB efflux
transporters (P-gp, BCRP), preclinical data in rats supporting
similar temporal profiles of TAK-285 disposition in brain
tissue and systemic circulation [24], and lack of a large fluc-
tuation in plasma TAK-285 concentrations over the steady-
state dosing interval (mean PTR of 2.8). Importantly, the re-
sults of these calculations indicate that the geometric mean
and individual values of steady-state average unbound con-
centrations achieved in CSF at 400 mg BIDwere all below the
HER2 kinase IC50 (Fig. 4b). These data indicate that biolog-
ically relevant levels of target inhibition are not expected to be
observed in human CNS after treatment with TAK-285 at the
MTD/RP2D.
A key consideration associated with this interpretation is
that the CSF distribution of TAK-285 was evaluated in
patients without CNS metastases in this study. Higher local
levels of distribution of TAK-285 may still be possible
within regions of brain metastases, where the BBB may be
partially compromised. Even though it is a substrate for
Table 5 Descriptive statistics of CSF distribution parameters of TAK-
285 at 400 mg BID (n=7)
Parameter Mean (%CV) Range of individual values
fu,p,% 0.097 (34.9) 0.054–0.158
fu,CSF, % 23.7 (34.1) 12.5–38.7
Cu,CSF:Cu,p, ratio 0.663 (22.8) 0.404–0.828
Css,avg,u,CSF, ng/mL 1.54 (74.0)
a 0.514–4.27
BID twice daily, CSF cerebrospinal fluid; Css,avg,u,CSF mean, unbound
steady-state concentration in CSF; Cu,CSF unbound concentration in
CSF; Cu,p unbound concentration in plasma; fu,CSF unbound fraction
in CSF; fu,p unbound fraction in plasma;%CV percentage coefficient of
variation
a Geometric mean (%CV); n=5
Unbound Plasma TAK-285 Concentration, ng/mL

















































Fig. 4 Cerebrospinal fluid (CSF) distribution of TAK-285. a Relation-
ship between the measured unbound CSF concentration (CCSF) and the
concurrently measured unbound plasma concentration of TAK-285 (Cu,p).
The symbols represent data from 7 individual patients, the solid line is a
linear regression fit to the data, the dashed lines represent the 95 %
confidence interval of the fitted linear relationship, and the dotted line is
the line of unity for equivalence of unbound CSF and unbound plasma
concentrations. b Individual values of the calculated steady-state average
unbound concentration of TAK-285 in CSF (Css,avg,u,CSF) in 5 patients, in
comparison with the 50% inhibitory concentration (IC50) for inhibition of
human epidermal growth receptor 2 (HER2) by TAK-285. Concentra-
tions achieved in all patients were below the HER2 IC50
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efflux transporters, lapatinib has demonstrated limited
antitumor activity in patients with brain metastases from
HER2+ breast cancer. In a single-arm phase 2 trial (N=242),
the objective response rate to lapatinib monotherapy was 6 %
and the clinical benefit rate was 43 %; 8 % of patients
experienced a ≥50 % reduction in CNS tumor size [14].
Intratumoral levels of lapatinib were not assessed in that study,
but it is plausible that access of lapatinib to tumor tissue may
be aided by a compromised BBB. In an experimental model of
HER2+ brain metastases, intratumoral lapatinib levels were
variable and correlated with altered blood-tumor barrier per-
meability [12]. However, preventing progression of
micrometastases will require drug availability within the
CNS in regions of preserved BBB integrity, as has been
discussed for malignant gliomas [30]. Additionally, the degree
of disruption of the BBB because of brain metastasis can be
highly variable between patients with metastatic breast cancer.
It has been reported that HER2+ brain metastases tend to be
associated with preservation of the BBB, whereas BBB dis-
ruption frequently occurs in CNSmetastases of triple-negative
or basal-type breast cancers [31]. Therefore, achievement of
bioactive exposures across an intact BBB may still be impor-
tant for advancement of clinical therapeutics for HER2+ met-
astatic breast cancer.
The lack of objective responses indicates that TAK-285
offers no advantage over currently available and emerging
therapies such as the HER2 dimerization inhibitor
pertuzumab. The phase 3 CLEOPATRA trial enrolled 808
patients with metastatic HER2+ breast cancer; patients had
not received prior chemotherapy or biologic therapy for their
metastatic disease [32]. In that study, the combination of
pertuzumab plus trastuzumab and docetaxel significantly
extended progression-free survival compared with
trastuzumab plus docetaxel alone (18.5 vs 12.4 months;
P<.001), and the objective response rate in the pertuzumab
arm was 80 % [32]. The pertuzumab/trastuzumab/docetaxel
combination received FDA approval in June 2012 [33].
Trials with the investigational HER2-targeted agent
trastuzumab emtansine also have shown promising results.
In a single-arm phase 2 study that enrolled heavily pretreated
patients (N=110) with refractory HER2+ disease, the overall
response rate was 35 % and the clinical benefit rate was 48 %
[34]. This agent was compared with the combination of
lapatinib and capecitabine in a large phase 3 study in
HER2+ patients (N=991). An interim analysis showed that
trastuzumab emtansine was associated with significantly
longer progression-free survival (9.6 vs 6.4 months,
P<.0001) and fewer serious AEs [35, 36]. If approved,
trastuzumab emtansine could be an important therapeutic
option for patients with HER2+ disease.
Treatment of advanced metastatic breast cancer remains a
challenge; the high incidence of brain metastases among
HER2+ patients is of particular concern. The development
of new HER2 kinase inhibitors that can cross the BBB and
achieve biologically significant levels of CNS exposure is
needed and is the subject of ongoing research.
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